Literature DB >> 426511

Pharmacology of cinoxacin in humans.

H R Black, K S Israel, R L Wolen, G L Brier, B D Obermeyer, E A Ziege, J D Wolny.   

Abstract

Cinoxacin was almost completely absorbed when given orally and was found to be approximately 60 to 70% protein bound. Peak serum concentrations were reached within 2 h, and detectable serum concentrations persisted up to 12 h after administration of 0.25-, 0.5-, and 1-g multiple oral doses. Although food delayed the absorption and caused a 30% reduction in mean peak serum concentrations, the overall 24-h urinary recovery was not significantly altered. Approximately 50 to 55% of the drug was excreted in the urine as unchanged drug. At 12 h, urine concentrations were still above the minimal inhibitory concentration for most common gram-negative urinary pathogens. Cinoxacin was well tolerated when administered to 23 volunteers from 10 to 28 days. Resistance among fecal isolates initially susceptible to cinoxacin was not observed in nine volunteers who were administered 0.5 g every 12 h for 4 to 28 days.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 426511      PMCID: PMC352627          DOI: 10.1128/AAC.15.2.165

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Studies on cinoxacin. 1. In vitro activity of cinoxacin, as compared to nalidixic acid, against urinary tract pathogens.

Authors:  P A Mårdh; S Collen; K E Andersson
Journal:  J Antimicrob Chemother       Date:  1977-09       Impact factor: 5.790

2.  Management of simple ureterolithotomy closure.

Authors:  V L Carpiniello; P M Hanno; T R Malloy; A J Wein
Journal:  Urology       Date:  1977-10       Impact factor: 2.649

3.  Studies on cinoxacin. 2. Assay of cinoxacin in body fluids and tissues.

Authors:  K E Andersson; S Collen; P A Mårdh
Journal:  J Antimicrob Chemother       Date:  1977-09       Impact factor: 5.790

4.  Compound 64716, a new synthetic antibacterial agent.

Authors:  W E Wick; D A Preston; W A White; R S Gordee
Journal:  Antimicrob Agents Chemother       Date:  1973-10       Impact factor: 5.191

5.  Serum protein binding of the aminoglycoside antibiotics.

Authors:  R C Gordon; C Regamey; W M Kirby
Journal:  Antimicrob Agents Chemother       Date:  1972-09       Impact factor: 5.191

6.  Cinoxacin: in vitro antibacterial studies of a new synthetic organic acid.

Authors:  R M Lumish; C W Norden
Journal:  Antimicrob Agents Chemother       Date:  1975-02       Impact factor: 5.191

7.  Antibacterial activity of cinoxacin in vitro.

Authors:  H Giamarellou; G G Jackson
Journal:  Antimicrob Agents Chemother       Date:  1975-05       Impact factor: 5.191

8.  Studies on cinoxacin. 3. Concentrations of cinoxacin in serum, urine and tissues of urological patients.

Authors:  S Colleen; K E Andersson; P A Mårdh
Journal:  J Antimicrob Chemother       Date:  1977-11       Impact factor: 5.790

9.  In vitro antimicrobial activity of cinoxacin against 2,968 clinical bacterial isolates.

Authors:  R N Jones; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1976-07       Impact factor: 5.191

10.  Cinoxacin concentrations in plasma, urine and prostatic tissue after oral administration to man.

Authors:  R A Burt; T Morgan; J P Payne; R M Bonner
Journal:  Br J Urol       Date:  1977-04
View more
  7 in total

1.  Influence of urinary pH on the pharmacokinetics of cinoxacin in humans and on antibacterial activity in vitro.

Authors:  R H Barbhaiya; A U Gerber; W A Craig; P G Welling
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

2.  Comparative pharmacokinetic profiles of cinoxacin and pipemidic acid in humans.

Authors:  J M Brogard; F Comte; J Lavillaureix
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983 Jul-Sep       Impact factor: 2.441

3.  Experiences on the efficacy and safety of nalidixic acid, oxolinic acid, cinoxacin and norfloxacin in the treatment of urinary tract infections (UTI).

Authors:  M S Sabbour; M A El Bokl; L M Osman
Journal:  Infection       Date:  1984 Nov-Dec       Impact factor: 3.553

4.  Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.

Authors:  W J Wijnands; T B Vree; A M Baars; C L van Herwaarden
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 5.  Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections.

Authors:  T S Sisca; R C Heel; J A Romankiewicz
Journal:  Drugs       Date:  1983-06       Impact factor: 9.546

6.  Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function.

Authors:  S Maigaard; N Frimodt-Möller; P G Welling; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

7.  Pharmacokinetics: metabolism and renal excretion of quinolones in man.

Authors:  T B Vree; W J Wijnands; P J Guelen; A M Baars; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1986-02-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.